ESC Congress 2022 (Photo by Kyle LaHucik)
#ESC22: BMS-J&J’s milvexian misses composite endpoint, but duo to push drug forward with signs of secondary stroke prevention and ‘flat bleeding curve’
BARCELONA — Bristol Myers Squibb and J&J’s Janssen look to move forward with a Phase III of their factor XIa drug in preventing secondary stroke …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.